Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Janux Therapeutics, Inc.NASDAQ: JANX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$24.36M, compared with -$23.51M a year earlier. Trailing-twelve-month income before tax was -$114.48M.

Context

  • Income before tax amounted to 1136.3% of revenue in FY2025, up 484.6 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$24.36M or moves back toward the trailing-twelve-month quarterly average of -$28.62M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$24.36M+23.7% QoQ
Last fiscal yearDec 2025
-$113.63M-64.7% YoY
LTMMar 2026
-$114.48M-47.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.6%——
1 year-64.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(113.63M) USD
Year-over-year change
-64.7%

Income Before Tax vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.3% is the 8th highest of 10, against a peer median of -26.9%.
  • Income before tax amounts to 529.7% of revenue for JANX, versus a peer median of 160.0%.
JANX Competitors
Income Before Tax for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$32.2M USD+114.5%—2.4%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$58.91M USD-240.8%—165.7%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$68.17M USD-23.5%——
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M USD-29.5%—45.2%
JANXJanux Therapeutics, Inc.LTM Mar 2026-$114.48M USD-47.3%—529.7%
STROSutro Biopharma, Inc.LTM Mar 2026-$153.72M USD+36.7%—154.3%
IMTXImmatics N.V.LTM Mar 2026-€215.35M EUR-1111.0%—577.4%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$221.04M USD-23.7%——
IMNMImmunome, Inc.LTM Sep 2026-$282.65M USD-26.9%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$309.11M USD-37.7%—275986.6%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —-26.9%—160.0%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.